Novel GPBAR1 agonist and RORγt inverse agonist: a dual-action approach for treating Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic disorders characterized by dysregulated immune responses and persistent inflammation. Recent studies suggest that bile acid receptors, particularly GPBAR1, and the transcription factor RORγt play critical roles in modulating intestinal inflammation. This study evaluates the therapeutic potential of ROR107, a dual GPBAR1 agonist and RORγt inverse agonist, in IBD models